Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACXP Acurx Pharmaceuticals, LLC*

Pre-Mkt 03-24 08:12:14 EDT

4.53

-1.07

-19.20%

盘前4.78

+0.25+5.61%

08:09 EDT

High5.59	Low4.43	Vol725.58K
Open5.51	D1 Closing5.60	Amplitude20.71%
Mkt Cap12.92M	Tradable Cap10.94M	Total Shares2.86M
T/O3.55M	T/O Rate30.01%	Tradable Shares2.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACXP","market":"US","secType":"STK","nameCN":"Acurx Pharmaceuticals, LLC*","latestPrice":4.525,"timestamp":1774296000000,"preClose":5.6,"halted":0,"volume":725578,"hourTrading":{"tag":"盘前","latestPrice":4.7788,"preClose":4.525,"latestTime":"08:09 EDT","volume":15405,"amount":74207.317665,"timestamp":1774354171204,"change":0.2538,"changeRate":0.056088,"amplitude":0.088398},"delay":0,"changeRate":-0.1919642857142856,"floatShares":2418100,"shares":2855025,"eps":-5.32,"marketStatus":"Pre-Mkt","change":-1.075,"latestTime":"03-24 08:12:14 EDT","open":5.51,"high":5.59,"low":4.43,"amount":3550473.7297119997,"amplitude":0.207143,"askPrice":5.08,"askSize":1,"bidPrice":4.7,"bidSize":35,"shortable":0,"etf":0,"ttmEps":-5.32,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774359000000},"marketStatusCode":1,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":4.525,"preHourTrading":{"tag":"盘前","latestPrice":4.7788,"preClose":4.525,"latestTime":"08:09 EDT","volume":15405,"amount":74207.317665,"timestamp":1774354171204,"change":0.2538,"changeRate":0.056088,"amplitude":0.088398},"postHourTrading":{"tag":"盘后","latestPrice":4.54,"preClose":4.525,"latestTime":"19:58 EDT","volume":16694,"amount":77252.3175,"timestamp":1774310283871,"change":0.015,"changeRate":0.003315,"amplitude":0.066298},"volumeRatio":0.14804855929102162,"impliedVol":1.1448,"impliedVolPercentile":0.6703},"requestUrl":"/m/hq/s/ACXP/wiki","defaultTab":"wiki","newsList":[{"id":"2621069667","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069667","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069667?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:16","pubTimestamp":1774350967,"startTime":"0","endTime":"0","summary":"Netgear  shares were 12% higher pre-bell Tuesday after the Federal Communications Commission banned the import of all new foreign-made consumer routers.Jefferies Financial  stock was up 8% following a Financial Times report that Sumitomo Mitsui Financial Group  is considering acquiring the US-based investment bank.Sol-Gel Technologies  shares were 7% higher, a day after the company said it has priced an oversubscribed underwritten offering of ordinary shares for gross proceeds of about $33.1 million.Acurx Pharmaceuticals  stock was up 6%, reversing from Monday's slide.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4127","BK4539","NTGR","ACXP","BK4207","BK4139","BK4020","BK4007","SMFG","JEF","BK4559","SLGL","BK4563"],"gpt_icon":0},{"id":"2619812269","title":"Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619812269","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619812269?lang=en_us&edition=fundamental","pubTime":"2026-03-14 23:50","pubTimestamp":1773503409,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvalent (NUVL – Research Report) and Acurx Pharmace...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-nuvalent-nuvl-acurx-pharmaceuticals-acxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-nuvalent-nuvl-acurx-pharmaceuticals-acxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSG","BK4139","NUVL","BK4588","LU0128526141.USD","XBI","BK4112","BLSX","ACXP","BK4137","BK4539","BK4563","LABU","LU0029874061.USD","BK4581","BK4585"],"gpt_icon":0},{"id":"2619114413","title":"Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2619114413","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619114413?lang=en_us&edition=fundamental","pubTime":"2026-03-14 01:35","pubTimestamp":1773423336,"startTime":"0","endTime":"0","summary":"In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Acurx Pharmaceuticals, with a price target of $10...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/acurx-pharmaceuticals-acxp-gets-a-buy-from-alliance-global-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/acurx-pharmaceuticals-acxp-gets-a-buy-from-alliance-global-partners-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACXP","BK4539","BK4563"],"gpt_icon":0},{"id":"2619112281","title":"Acurx price target lowered to $10 from $20 at Alliance Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2619112281","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619112281?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:50","pubTimestamp":1773420620,"startTime":"0","endTime":"0","summary":"Alliance Global lowered the firm’s price target on Acurx (ACXP) to $10 from $20 and keeps a Buy rating on the shares following the Q4 report. The f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acurx-price-target-lowered-to-10-from-20-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acurx-price-target-lowered-to-10-from-20-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACXP","BK4539","BK4563","BK4139"],"gpt_icon":0},{"id":"2619190717","title":"Acurx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2619190717","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619190717?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:31","pubTimestamp":1773408706,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryAcurx Pharmaceuticals Inc ACXP.OQ reported a quarterly adjusted loss of 31 cents per share for the quarter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N4011BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP","BK4539","BK4139","BK4563"],"gpt_icon":0},{"id":"2619199970","title":"Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend","url":"https://stock-news.laohu8.com/highlight/detail?id=2619199970","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619199970?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:10","pubTimestamp":1773400205,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spendOverviewUS biopharmaceutical firm's Q4 net loss narrowed as R&D and G&A expenses declinedCompany ended Q4 with $7.6 mln cash, up from $3.7 m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL1N4010F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ACXP","BK4563"],"gpt_icon":0},{"id":"2619199801","title":"Acurx Pharmaceuticals Q4 EPS $(0.73) Beats $(1.65) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2619199801","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619199801?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:01","pubTimestamp":1773399718,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(1.65) by 55.62 percent. This is a 78.53 percent increase over losses of $(3.40) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51236175/acurx-pharmaceuticals-q4-eps-0-73-beats-1-65-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","ACXP","BK4563"],"gpt_icon":0},{"id":"2619199383","title":"Acurx Pharmaceuticals Q4 EPS USD -0.73","url":"https://stock-news.laohu8.com/highlight/detail?id=2619199383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619199383?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:01","pubTimestamp":1773399660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nPLX132728:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","ACXP","BK4539","BK4139"],"gpt_icon":0},{"id":"2619365199","title":"Press Release: Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619365199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619365199?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:01","pubTimestamp":1773399660,"startTime":"0","endTime":"0","summary":"STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.  , a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025.Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:. -- In October 2025, the Company received gross proceeds from the exercise of. 170,068 Series F Warrants of approximately $1.4 million.-- Also in October 2025, we were one of five companies to make a formal. presentation at IDWeek in Atlanta at the session entitled New. Antimicrobials in the Pipeline. Presenting on behalf of Acurx were Dr.Michael Silverman, our Medical Director, and Dr. Kevin Garey, Professor. and Chair, University of Houston College of Pharmacy and the Principal. Investigator for microbiology and microbiome aspects of the ibezapolstat. clinical tri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4563","R","BK4139","BK4232","ACXP","BK4539","BK4588","LABU","BK4022","BK4215","MAA"],"gpt_icon":0},{"id":"2619193658","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2619193658","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619193658?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:00","pubTimestamp":1773396000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·KE Hldgs ADR                                    4Q       .11    6:00 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTY","ESLT","DERM","ARX","BTM","FLD","BZ","ACXP","ALVO","CBUS","ACN","CREX","DLTR","CTMX","BETR","DRI","EQPT","ABEO","ETON","CELC","ERAS","BIOA","ECOR","DCGO","CDNL","ANDG","CAAP","ARCO","DOCU","AEBI","ASRT","BEKE","ELDN","ATAT","DRIO","BRAG","AVR","CSIQ","AGEN","BDTX","DLO","CAL","FIVE","ASO","AVAH","FDX","ZTO","EVEX","BGSI"],"gpt_icon":1},{"id":"2618134827","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134827","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134827?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:13","pubTimestamp":1773317618,"startTime":"0","endTime":"0","summary":"Netskope  shares were down 16% in Thursday's premarket activity, a day after the company issued higher-than-expected fiscal 2027 adjusted loss outlook.Acurx Pharmaceuticals  stock was down 9%, erasing Wednesday's rise.Honda Motor  shares were 7% lower after the company said it now expects a fiscal 2026 loss of 105.07 Japanese yen  to 172.62 yen per share, compared with the previous projection of earnings of 75.05 yen per share.Li Auto  stock was down 2.5% after the company posted lower Q4 adjusted earnings and revenue in addition to issuing lower-than-expected Q1 sales guidance.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7162","BK4551","BK4555","BK4539","HEWJ","BK4099","BK4139","BK4526","BK7062","BK4503","BK4563","BK4097","ACXP","FXY","BK7005","HMC","EVS.SI","BK4548","BK4585","NTSK","BK4588"],"gpt_icon":1},{"id":"2618920248","title":"Why Is Acurx Pharmaceuticals Stock Up Over 105% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618920248","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618920248?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:45","pubTimestamp":1773254700,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc shares are trading sharply higher Wednesday afternoon despite a lack of company-specific news during the session.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/11/Woman-Hand-Holding-Healthcare-Medical-Ic_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/11/Woman-Hand-Holding-Healthcare-Medical-Ic_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51196489/why-is-acurx-pharmaceuticals-acxp-stock-up-over-105-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51196489/why-is-acurx-pharmaceuticals-acxp-stock-up-over-105-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4539","BK4139","ACXP","BK4563"],"gpt_icon":0},{"id":"2618420359","title":"Acurx Pharmaceuticals Inc  expected to post a loss of $1.01 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2618420359","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618420359?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:32","pubTimestamp":1773232351,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc  expected to post a loss of $1.01 a share - Earnings Preview Acurx Pharmaceuticals Inc ACXP.OQ ACXP.O is expected to  report resultson March 13 for the period ending December","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL8N3ZZ1HE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ACXP","BK4563"],"gpt_icon":0},{"id":"2618629960","title":"Acurx Pharmaceuticals: Effective April 1, 2026, CEO & Executive Chairman Salaries Reduced to $495,000, CFO Salary Reduced to $360,000 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618629960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618629960?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:06","pubTimestamp":1773061572,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX0GJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","ACXP","BK4539","BK4139"],"gpt_icon":0},{"id":"2618629930","title":"Acurx Pharmaceuticals Inc - Approves Voluntary Reductions to Executive Base Salaries - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618629930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618629930?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:06","pubTimestamp":1773061572,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX0GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACXP","BK4539","BK4563"],"gpt_icon":0},{"id":"2618625582","title":"Acurx Pharmaceuticals Inc - Trial Start-up for Rcdi to Begin This Month; First Patient Expected Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625582","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625582?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:01","pubTimestamp":1773057660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA8ZVFHY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACXP","BK4139","BK4563","BK4539"],"gpt_icon":0},{"id":"2618625318","title":"Acurx Announces New Ibezapolstat Clinical Trial Program in Patients With Recurrent Cdi That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. Difficile Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625318?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:01","pubTimestamp":1773057660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA8ZVFHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4539","ACXP","BK4139"],"gpt_icon":0},{"id":"2618253116","title":"Acurx Pharmaceuticals Inc - Program Ready to Advance to Phase 3 International Clinical Trials for Cdi","url":"https://stock-news.laohu8.com/highlight/detail?id=2618253116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618253116?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:01","pubTimestamp":1773057660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA8ZVFHY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","BK4539","ACXP"],"gpt_icon":0},{"id":"2611483476","title":"Acurx Pharmaceuticals Inc. to discuss full year and fourth quarter financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2611483476","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611483476?lang=en_us&edition=fundamental","pubTime":"2026-02-16 21:01","pubTimestamp":1771246875,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc. will announce its full year and fourth quarter 2025 financial results on Friday, March 13, 2026, at 8:00 a.m. ET before the U.S. financial markets open. President and Chief Executive Officer David P. Luci and Chief Financial Officer Robert G. Shawah will host a conference call to discuss the results and provide a business update. For international toll-free access numbers, see participant International Toll-Free access numbers.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nNDLb32bN0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","BK4539","ACXP"],"gpt_icon":0},{"id":"2611483410","title":"Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2611483410","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611483410?lang=en_us&edition=fundamental","pubTime":"2026-02-16 21:01","pubTimestamp":1771246860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nTUABLGNFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4539","BK4139","ACXP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acurxpharma.com","stockEarnings":[{"period":"1week","weight":-0.0593},{"period":"1month","weight":1.7259},{"period":"3month","weight":0.2929},{"period":"6month","weight":0.0904},{"period":"1year","weight":-0.4656},{"period":"ytd","weight":0.8173}],"compareEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0494},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.0087},{"period":"1year","weight":0.1621},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.08634},{"month":2,"riseRate":0,"avgChangeRate":-0.144545},{"month":3,"riseRate":0.4,"avgChangeRate":0.27333},{"month":4,"riseRate":0.5,"avgChangeRate":0.00047},{"month":5,"riseRate":0.5,"avgChangeRate":-0.04935},{"month":6,"riseRate":0.5,"avgChangeRate":0.118659},{"month":7,"riseRate":0,"avgChangeRate":-0.160175},{"month":8,"riseRate":0.2,"avgChangeRate":-0.087422},{"month":9,"riseRate":0,"avgChangeRate":-0.115354},{"month":10,"riseRate":0.6,"avgChangeRate":0.545147},{"month":11,"riseRate":0.2,"avgChangeRate":-0.181708},{"month":12,"riseRate":0.4,"avgChangeRate":-0.094208}],"exchange":"NASDAQ","name":"Acurx Pharmaceuticals, LLC*","nameEN":"Acurx Pharmaceuticals, LLC*"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acurx Pharmaceuticals, LLC*(ACXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acurx Pharmaceuticals, LLC*,ACXP,Acurx Pharmaceuticals, LLC*股票,Acurx Pharmaceuticals, LLC*股票老虎,Acurx Pharmaceuticals, LLC*股票老虎国际,Acurx Pharmaceuticals, LLC*行情,Acurx Pharmaceuticals, LLC*股票行情,Acurx Pharmaceuticals, LLC*股价,Acurx Pharmaceuticals, LLC*股市,Acurx Pharmaceuticals, LLC*股票价格,Acurx Pharmaceuticals, LLC*股票交易,Acurx Pharmaceuticals, LLC*股票购买,Acurx Pharmaceuticals, LLC*股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acurx Pharmaceuticals, LLC*(ACXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}